Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flotetuzumab in relapsed AML post-transplant
NCT05506956Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flotetuzumab in acute myeloid leukemia (AML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose at 6 months. Started Oct 2022; status: completed.
02
Drugs
flotetuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05506956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506956.